Prevailing cases of Cancer to upsurge the market growth of the Global Cancer Monoclonal Antibodies Market
Monoclonal antibodies are engineered proteins of the immune system that specify in the treatment of cancer and are created in the laboratory. Immunoglobulins or antibodies are protective proteins that locate and kill the pathogens such as bacteria and viruses which harm the immune system. Dr. Warner Greene, director of Center for HIV Cure Research at the Gladstone Institutes in San Francisco says "They're released from the cell and they circulate & go out to hunt the pathogens,". Monoclonal antibodies specify in treating a large number of inflammatory & autoimmune diseases, especially cancer. These engineered antibodies are designed in such a way that they destroy only the cancerous cells and provide no harm to the healthy cells and are equally as efficient as the natural antibodies produced by the body. Hence, cancer monoclonal antibodies are widely used in the treatment of cancer as they are way more accurate & efficient in treating cancer than the traditional methods such as drugs and chemotherapy.
The high prevalence of cancer globally is the major factor driving the growth of the global cancer monoclonal antibodies market. World Health Organization states cancer is the second leading cause of death worldwide, accounting for about 9.8 million deaths, or one in six deaths globally. Colorectal, cervical, lung, and thyroid cancer are more frequently seen in women whereas, prostate, colorectal, liver & lung cancer is more prevalent in men. FDA-approved monoclonal antibodies such as Tixagevimab and cilgavimab, are designed in such a way that the virus cannot enter human cells.